Cardiac arrhythmia assessment in phase IV clinical studies

Cardiac Safety of Noncardiac Drugs: Practical Guidelines for Clinical Research and Drug Development

Volumn , Issue , 2005, Pages 229-237

  Faich, Gerald A ^a   Stemhagen, Annette ^b  

^a Pharmaceutical Safety Assessments Inc   (United States)

^b Strategic Development Services   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84889875556     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-59259-884-7_13     Document Type: Chapter

References (19)

1. Mathieu M. New Drug Development: A Regulatory Overview , 4th ed. Waltham, MA: Parexel International Corp., 1997
2. Liberman UA, Hirsch LJ. Esophagitis and alendronate. N Engl J Med 1996;335:1069-1070.
3. Meinert CL. Clinical Trials. Design, Conduct and Analysis. NY: Oxford University Press, 1986.
4. Faich GA. Adverse drug reaction monitoring. New Engl J Med 1986;314:1589-1592.
5. Faich GA. US adverse drug reaction surveillance 1989-1994. Pharmacoepidem and Drug Safety 1996;5:393-398.
6. FDA/Pharma Task Force to Assess QT Risk, FDC Weekly (Pink Sheet). Nov 1, 1999, pp. 15-17.
7. Michels KB, Faich GA. Linked databases and epidemiology, J Clinical Research and Pharmacoepidemiology 1991;5:11-18.
8. Hennessy S, Bilker W, Knauss JS, Margolis DJ, Kimmel S, et al. Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs. Brit Med J 2002;325:1070.
9. Hanrahan JP, Choo PW, Carlson W, Greineder D, Faich GA, Platt R. Terfenadine-Associated ventricular arrhythmias and QTc interval prolongation. A retrospective cohort comparison with other antihistamines among members of a health maintenance organization. Ann Epidemiol 1995;5:201-209.
10. Lesko SM, Mitchell AA. Use of randomized controlled trials for phramacoepidemiology studies. In Pharmacoepidemiology 3rd ed. Strom BL, ed. NY: John Wiley & Sons, 2000, pp. 539-552.
11. Yusuf S Collins R, Peto R.Why do we need some large simple randomized trials? Stat in Med 1984; 3:409-420.
12. Peto R, Collins R, Gray R, Large-scale randomized evidence: Large, simple trials and overviews of trials. J Clin Epidemiol 1995;48:23-40.
13. Ellenberg S, Fleming TR, DeMets DL. Data Monitoring Committees in Clinical Trials. NY: John Wiley & Sons, 2003.
14. Franceis T, Korns R, Voight R, et al. An evaluation of the 1954 poliomyelitis vaccine trails. Am J Public Health 1955;45:1-50.
15. Steering Committee of the Physicians Health Study Research Group. Final report on the aspirin component of the ongoing Physicians Health Study. New Engl J Med 1989;321:129-135.
16. Lesko SM, Mitchell AA. An assessment of the safety of pediatric ibuprofen. A practitioner-based randomized clinical trial. J Amer Med Assoc 1996;275:986.
17. Castle W, Fuller R, Hall J, Palmer R. Comparison of salmeterol with salbutamol. J Brit Med 1993;306: 1034-1037
18. Faich GA, Morganroth J, Whitehouse AB, Brar JS, Arcuri P, Kowalshy SF, Haverstock DC, Celesk, RA, Church DA. Clinical experience with moxifloxacin in patients with respiratory tract infections. Ann Pharmacother 2004;38:140.
19. Kessler D, Rose L, Temple R. et al. Seeding trials-Therapeutic class wars-drug promotion. New Engl J Med 1994;331:1350-1353.